Banco Bilbao Vizcaya Argentaria S.A. Has $2.53 Million Stake in Zoetis Inc. $ZTS

Banco Bilbao Vizcaya Argentaria S.A. lowered its stake in Zoetis Inc. (NYSE:ZTS) by 20.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,216 shares of the company’s stock after selling 4,284 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Zoetis were worth $2,528,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Lindbrook Capital LLC grew its position in Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares in the last quarter. Scott & Selber Inc. boosted its position in Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after buying an additional 67 shares during the period. Secure Asset Management LLC raised its stake in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC increased its position in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after buying an additional 72 shares in the last quarter. Finally, CVA Family Office LLC lifted its position in shares of Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after buying an additional 74 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.3%

ZTS opened at $120.78 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $117.26 and a fifty-two week high of $181.85. The firm has a 50 day simple moving average of $140.92 and a 200 day simple moving average of $151.44. The company has a market cap of $53.23 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the business earned $1.58 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. BTIG Research reduced their price target on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Morgan Stanley cut their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average target price of $180.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.